Research-collaboration-Gubra-obesity-treatment

Boehringer Ingelheim and Gubra Join Forces to Identify and  Validate Innovative Peptides for the Treatment of ObesityThe research agreement builds upon the successful relationship between Boehringer Ingelheim and Gubra and expands Boehringer Ingelheim ’s research into approaches with first in class potential for the treatment of obesity Obesity is a complex cardiometabolic disease with growing global prevalence and limited treatment options that are not sufficiently effective or are associated with adverse events
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news